Success Metrics

Clinical Success Rate
100.0%

Based on 10 completed trials

Completion Rate
100%(10/10)
Active Trials
0(0%)
Results Posted
20%(2 trials)

Phase Distribution

Ph phase_3
2
20%
Ph phase_1
6
60%
Ph phase_2
1
10%

Phase Distribution

6

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
6(66.7%)
Phase 2Efficacy & side effects
1(11.1%)
Phase 3Large-scale testing
2(22.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

10 of 10 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(10)

Detailed Status

Completed10

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 16 (66.7%)
Phase 21 (11.1%)
Phase 32 (22.2%)

Trials by Status

completed10100%

Recent Activity

0 active trials
Showing 5 of 10
completedphase_3

The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial

NCT00799903
completedphase_1

Study to Evaluate Darapladib in Moderately Hepatically Impaired Subjects

NCT01154114
completedphase_1

Study to Determine the Effect of Repeated Administration of Diltiazem on the Pharmacokinetics of Darapladib (Sb-480848).

NCT01852565
completedphase_1

Effect of Darapladib on Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus (T2DM)

NCT02058641
completedphase_1

Pharmacokinetic Interaction of Darapladib and CYP 3A4 in Healthy Subjects

NCT01873339
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT00799903Phase 3

The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial

Completed
NCT01154114Phase 1

Study to Evaluate Darapladib in Moderately Hepatically Impaired Subjects

Completed
NCT01852565Phase 1

Study to Determine the Effect of Repeated Administration of Diltiazem on the Pharmacokinetics of Darapladib (Sb-480848).

Completed
NCT02058641Phase 1

Effect of Darapladib on Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus (T2DM)

Completed
NCT01873339Phase 1

Pharmacokinetic Interaction of Darapladib and CYP 3A4 in Healthy Subjects

Completed
NCT01067339Phase 3

Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Progenitor Cells and Coronary Atherosclerosis in Humans

Completed
NCT01506895Phase 2

A Phase 2 Clinical Study to Investigate Effects of Darapladib in Subjects With Diabetic Macular Edema

Completed
NCT00743860Phase 1

A Healthy Volunteer Pharmacokinetic Study of Single and Repeat Doses of SB-480848

Completed
NCT00411073Phase 1

Study Of The Effects Of SB 480848 (Darapladib) On The Electrical Conduction Of The Heart

Completed
NCT01636271

SB-480848 in Major Adverse Cardiovascular Events - Integrated Summary of Efficacy and Safety From the STABILITY Trial (LPL100601) and the SOLID-TIMI-52 Trial (SB-480848/033)

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10